RxDoctor Payments Data

Joseph Phillips, MD

Urology · Dothan, ALNPI 1013130186

Payments from drug & device makers

$3,223in general payments, 2019–2025

Across 134 payments — averaging $24.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$737
  • Sumitomo Pharma America, Inc.$517
  • Axonics, Inc.$299
  • Boston Scientific$280
  • Pfizer$237
  • Johnson & Johnson$204
  • plus $948 from 18 others

What the payments were for

  • Food & beverage$2,92991%
  • Education$2949%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,223 in reported general payments places this provider in the 45th percentile of 179 urology providers in Alabama.

See all urology providers in Alabama

Medicare billing

Part B allowed, 2024
$226,154
Medicare patients
869
Services billed
83,914

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide41$568,009
MyrbetriqMirabegron269$162,953
OctagamImmun Globg(Igg)/Malt/Iga Ov5011$44,743
Tamsulosin Hcl941$15,122
GemtesaVibegron27$14,146
Testosterone Cypionate160$6,472
Finasteride431$6,253
NitrofurantoinNitrofurantoin Macrocrystal152$6,216
Methenamine Hippurate55$4,177
Testosterone14$4,139
Estradiol49$3,988
Tadalafil63$2,933
Oxybutynin Chloride ErOxybutynin Chloride171$2,712
Solifenacin Succinate59$2,075
Ciprofloxacin Hcl258$1,742

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$737$730,962310 claims
PfizerOctagam$237$44,74311 claims
Sumitomo Pharma America, Inc.Gemtesa$517$14,14627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 179 urology providers in Alabama.

Other urology in Dothan

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →